Previous Close | 9.09 |
Open | 9.90 |
Bid | 0.00 x 900 |
Ask | 0.00 x 1100 |
Day's Range | 9.32 - 10.05 |
52 Week Range | 5.42 - 23.89 |
Volume | |
Avg. Volume | 289,011 |
Market Cap | 99.345M |
Beta (5Y Monthly) | 1.55 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -4.84 |
Earnings Date | Apr 01, 2024 - Apr 05, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 34.60 |
Subscribe to Yahoo Finance Plus to view Fair Value for ANVS
Investors need to pay close attention to Annovis Bio (ANVS) stock based on the movements in the options market lately.
As the saying goes, what goes up must come down. This adage holds true for three stocks. With the market seemingly inflated, it’s vital to identify the warning signs of potential crashes before they occur. These stocks hold solid weaknesses and red flags that could signal an imminent burst in their respective bubbles. The first one grapples with declining retail unit sales and deteriorating credit quality. The company wrestles with declining sales and mounting credit risks. The second one faces
MALVERN, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced panel participation in the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2024), taking place in Lisbon, Portugal March 5-9, 2024. Maria Maccecchini, PhD, Founder, President, and CEO of Annovis, will join a forum discussion focused on new approaches for alpha-synuclein (αSyn), LRK